ALL NEWS TODAY

[ ALL NEWS TODAY ]

Synosia Starts Phase II Efficacy Trial For Rufinamide

The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the United States. It will assess the efficacy and tolerability of rufinamide in up to 230 patients with general anxiety disorder, as measured by multiple psychometric assessment tools. Patients randomized to rufinamide will receive 250mg twice a day for one week followed by 500mg twice a day for seven weeks.
Comments: [0] / Post comment:
05 Jan 2009 22:19:50

Thriving in 2008: Approvals, Deals and Other Silver Linings - TMCnet

Thriving in 2008: Approvals, Deals and Other Silver Linings TMCnet - 14 for Banzel ( rufinamide ) as an adjunctive treatment for seizures in adults and children older than 4 years with Lennox-Gastaut syndrome, and the second on ...
22 Dec 2008 20:30:32

FDA Approved Drugs During 2008 - eMaxHealth.com

FDA Approved Drugs During 2008 eMaxHealth.com, NC - Banzel ( rufinamide ); For the treatment of seizures associated with Lennox-Gastaut syndrome in pediatrics and adults; Eisai; Approved November 2008 28. ...

Keywords:

ALL NEWS TODAY © PoznaiSebya.Com
Designer Padayatra Dmytriy